Yahoo · Sep 10, 2026
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AT
NASDAQ · ATAI
Atai Beckley N.V
Healthcare · Medical - Pharmaceuticals
$7.35
Up+$0.00 (+0.00%)
Updated Oct 8, 2026, 8:13 AM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.71M
- P/E ratio
- -5.12
- Dividend yield
- 91.84%
- 52-week range
- $3.27 – $7.45
- Volume
- 9.59M
- Avg. volume
- 3.82M
Price performance · ATAI
ATAI price history
1M range · 0 trading sessions · Daily adjusted prices
ATAI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ATAI news
The latest Smart Investors Daily articles mentioning ATAI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATAI research
Overview
Company profile and research snapshot.
Company profile
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.00
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Deutsche Bank | Hold | — |
| Jul 20, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 17, 2026 | Jones Trading | Hold | — |
| Jul 17, 2026 | Jefferies | Hold | — |
| Jul 16, 2026 | Maxim Group | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
ChartMill · Sep 5, 2026
Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen
ATAI Beckley (NASDAQ:ATAI) clears Minervini Trend Template & high-growth screen with strong momentum and accelerating sales/EPS growth.
Benzinga · Aug 31, 2026
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
